自身免疫性肝炎发作导致慢加急性肝衰竭:诊断与糖皮质激素治疗反应
在亚太地区2825例慢加急性肝衰竭(ACLF)患者中,82例(2.9%)符合自身免疫性肝炎(AIH)诊断,其中49%血清学阴性。28例(34%)接受糖皮质激素治疗者90天生存率75% vs 未接受者48.1%(P=0.02),ICU入住时间中位数1.5天 vs 4天(P<0.001)。结论认为AIH-ACLF在亚洲患者中并不少见,需低门槛行肝活检确诊。
要点
- AIH所致ACLF占ACLF患者的2.9%,近半数血清学阴性,确诊需肝活检。
- 接受激素治疗者90天生存率75% vs 48.1%(P=0.02),ICU停留中位1.5天 vs 4天(P<0.001)。
- 高龄、MELD>27、肝性脑病、纤维化≥F3者对激素反应不佳。
核心结论
- AIH表现为ACLF在亚洲患者中并不少见。
- 确诊需低门槛行肝活检,因近半数患者血清学阴性。
- 早期分层至激素治疗或肝移植(MELD>27、肝性脑病且纤维化≥F3)可缩短ICU停留并改善结局。
研究设计与样本
- 前瞻性招募并随访2012至2017年亚太肝病研究学会ACLF研究联盟(AARC)数据库中的AIH-ACLF患者。
- AIH诊断采用国际自身免疫性肝炎组评分或简化AIH评分,并需组织病理学证据。
- 共2825例ACLF患者,其中82例(2.9%)符合AIH标准,年龄42.1±18.1岁,70%为女性。
主要发现
- 基线平均胆红素18.6±8.2 mg/dL,Child-Turcotte-Pugh评分11.7±1.4,MELD评分27.6±6.5。
- 平均免疫球蛋白G为21.61±7.32 g/dL,97%病例升高≥1.1倍;49%血清学阴性。
- 90%患者有肝组织学资料,中位组织学活动指数10(四分位距7-12);90%有中至重度界面活动;56%有显著实质坏死(桥接和融合性坏死);42%有肝硬化。
- 28例(34%)接受激素治疗者ICU停留中位1.5天 vs 未接受者4天(P<0.001),90天生存率75% vs 48.1%(P=0.02),脓毒症发生率无显著差异(P=0.32)。
- 高龄、更严重肝病(MELD>27;敏感性83.3%,特异性78.9%,受试者工作特征曲线下面积0.86)、肝性脑病、纤维化分级≥F3者对激素治疗反应不佳。
关键数值与推荐
- AIH诊断采用国际自身免疫性肝炎组评分或简化AIH评分,并需组织病理学证据。
- 激素治疗组90天生存率75% vs 未治疗组48.1%(P=0.02)。
- 激素治疗组ICU停留中位1.5天 vs 未治疗组4天(P<0.001)。
- MELD>27预测激素反应不佳的敏感性83.3%,特异性78.9%,受试者工作特征曲线下面积0.86。
临床怎么用
- 作者认为AIH-ACLF在亚洲患者中并不少见,确诊需低门槛行肝活检。
- 作者建议早期分层至激素治疗或肝移植(MELD>27、肝性脑病且纤维化≥F3)以缩短ICU停留并改善结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune hepatitis (AIH) is considered less common in the Asia Pacific region. Due to this, AIH flare as a cause of acute on chronic liver failure (ACLF) is often overlooked and treatment delayed. We aimed at the defining clinical and histopathological spectrum and role of steroid therapy in AIH-ACLF. Patients with AIH-ACLF, prospectively recruited and followed between 2012 and 2017, were analyzed from the Asian Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) data base. Diagnosis of AIH was confirmed using International Autoimmune Hepatitis Group score or simplified AIH score with histopathological evidence. Of 2,825 ACLF patients, 82 (2.9%) fulfilled criteria of AIH (age 42.1 ± 18.1 years, 70% female). At baseline, mean bilirubin was 18.6 ± 8.2 mg/dL, Child-Turcotte-Pugh score was 11.7 ± 1.4, and Model for End-Stage Liver Disease (MELD) score was 27.6 ± 6.5. Mean immunoglobulin G was 21.61 ± 7.32 g/dL, and this was elevated ≥1.1 times in 97% of cases; 49% were seronegative. Liver histology was available in 90%, with median histological activity index of 10 (interquartile range, 7-12); 90% with moderate to severe interface activity; 56% showing significant parenchymal necrosis (bridging and confluent necrosis); and cirrhosis in 42%. Twenty-eight (34%) patients received steroid therapy and showed shorter intensive care unit (ICU) stay (median 1.5 versus 4 days, P < 0.001) and improved 90-day survival (75% versus 48.1%, P = 0.02) with comparable incidence of sepsis (P = 0.32) compared to those who did not. Patients of advanced age, more severe liver disease (MELD >27; 83.3% sensitivity, 78.9% specificity, area under the receiver operating characteristic curve 0.86), presence of hepatic encephalopathy, and fibrosis grade ≥F3 had an unfavorable response to corticosteroid therapy. Conclusion: AIH presenting as ACLF is not uncommon in Asian patients; a low threshold for liver biopsy is needed to confirm the diagnosis as nearly half the patients are seronegative; early stratification to steroid therapy or liver transplantation (MELD >27, hepatic encephalopathy in ≥F3) would reduce ICU stay and improve outcomes.
引用
- Anand L, Choudhury A, Bihari C, et al. Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy. Hepatology. 2019. PMID: 30113706. doi:10.1002/hep.30205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。